AVRICORE HEALTH CORPORATE UPDATE: 2024 record year, UK expansion on track

Core Insights - Avricore Health Inc. is expanding its HealthTab™ platform in the UK, emphasizing the role of pharmacists in chronic disease prevention and management [1][2] - The UK government is significantly investing in community pharmacies, with £645 million (approx. CAD $1.2 billion) pledged in 2024 and £617 million (approx. CAD $1.144 billion) in 2025 to enhance pharmacy-led services [5] - The company has concluded operations in Shoppers Drug Mart locations in Canada as of March 31, 2025, allowing for the redeployment of devices in Canada and the UK [3][4] Financial Performance - In 2024, total revenue increased by 37% year over year to $4,785,711, while gross profit rose by 56% to $1,880,306 [11] - The company reported a loss from operations of $668,977 in 2024, an improvement from a loss of $701,215 in 2023 [8] - Total assets decreased to $2,298,544 in 2024 from $2,538,205 in 2023, while total current liabilities dropped to $330,817 from $529,218 [8] HealthTab™ Expansion - The HealthTab™ platform launched in North East London in November 2024, targeting areas with high cardiovascular disease burdens [13] - The initiative is supported by local health authorities and aims to integrate with NHS digital systems to modernize care pathways [13][14] - The platform has already conducted over 930,000 blood pressure screenings in 6,000 pharmacies, demonstrating strong uptake [14][6] Future Strategy - The company plans to expand HealthTab™ into other major population centers in the UK, focusing on diverse demographics suitable for preventative health programs [15] - Following initial successes, the company aims to work with NHS stakeholders for broader adoption of HealthTab™, potentially integrating cholesterol testing into the Pharmacy First protocol [16] - Momentum is expected to grow throughout 2025 as NHS plans for expanding point-of-care testing in community pharmacies become clearer [17] Market Context - The point-of-care testing market is projected to reach $93.21 billion USD by 2030, indicating significant growth potential for HealthTab™ [19] - The UK government’s investment in pharmacy-led services aligns with the increasing demand for accessible healthcare solutions amid rising chronic disease rates [5][6]